This report investigates different options for using human papillomavirus (HPV) testing in cervical cancer prevention.
These options are evaluated by a stochastic model of the progression of pre-malignancy and its relationship to HPV infection.
Three screening policies are compared : 2 based on cytological screening, with or without HPV testing, and I in which HPV testing is the primary screening method.
A policy of HPV testing for women with mildly abnormal smears would have little effect on the overall incidence of invasive cancer when compared with a policy of repeat cytology, provided follow-up is efficient.
Moreover, the potential value of HPV testing as a primary screening method is strongly dependent on the proportion of neoplasias that are HPV-negative.
Important factors in assessing the future role of HPV testing would be cost-effectiveness and benefits from improved compliance.
Mots-clés Pascal : Tumeur maligne, Col utérus, Dépistage, Diagnostic, Papillomavirus humain, Papillomavirus, Papovaviridae, Virus, Infection, Homme, Appareil génital femelle pathologie, Col utérus pathologie, Virose
Mots-clés Pascal anglais : Malignant tumor, Uterine cervix, Medical screening, Diagnosis, Human papillomavirus, Papillomavirus, Papovaviridae, Virus, Infection, Human, Female genital diseases, Uterine cervix diseases, Viral disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0190845
Code Inist : 002B20C02. Création : 199608.